CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

Tonny Veenith, Benjamin A Fisher, Daniel Slade, Anna Rowe, Rowena Sharpe, David R Thickett, Tony Whitehouse, Matthew Rowland, James Scriven, Dhruv Parekh, Sarah J Bowden, Joshua S Savage, Duncan Richards, Julian Bion, Pamela Kearns, Simon Gates, CATALYST Trial Investigators

Research output: Contribution to journalArticlepeer-review

6 Downloads (Pure)

Abstract

INTRODUCTION: Severe SARS-CoV-2 infection is associated with a dysregulated immune response. Inflammatory monocytes and macrophages are crucial, promoting injurious, proinflammatory sequelae. Immunomodulation is, therefore, an attractive therapeutic strategy and we sought to test licensed and novel candidate drugs.

METHODS AND ANALYSIS: The CATALYST trial is a multiarm, open-label, multicentre, phase II platform trial designed to identify candidate novel treatments to improve outcomes of patients hospitalised with COVID-19 compared with usual care. Treatments with evidence of biomarker improvements will be put forward for larger-scale testing by current national phase III platform trials. Hospitalised patients >16 years with a clinical picture strongly suggestive of SARS-CoV-2 pneumonia (confirmed by chest X-ray or CT scan, with or without a positive reverse transcription PCR assay) and a C reactive protein (CRP) ≥40 mg/L are eligible. The primary outcome measure is CRP, measured serially from admission to day 14, hospital discharge or death. Secondary outcomes include the WHO Clinical Progression Improvement Scale as a principal efficacy assessment.

ETHICS AND DISSEMINATION: The protocol was approved by the East Midlands-Nottingham 2 Research Ethics Committee (20/EM/0115) and given urgent public health status; initial approval was received on 5 May 2020, current protocol version (V.6.0) approval on 12 October 2020. The MHRA also approved all protocol versions. The results of this trial will be disseminated through national and international presentations and peer-reviewed publications.

TRIAL REGISTRATION NUMBERS: EudraCT2020-001684-89, ISRCTN40580903.

Original languageEnglish
Article numbere050202
Number of pages11
JournalBMJ open
Volume11
Issue number11
DOIs
Publication statusPublished - 11 Nov 2021

Keywords

  • Adult
  • COVID-19
  • Clinical Trials, Phase II as Topic
  • Hospitalization
  • Humans
  • Multicenter Studies as Topic
  • Research
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults'. Together they form a unique fingerprint.

Cite this